• News
  • SAN DIEGO
  • BioTech

Neurocrine nets $9.5 million in 4Q

Neurocrine Biosciences Inc. (Nasdaq: NBIX) Friday announced its net income for the fourth quarter of 2012 rose to $9.5 million or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
NBIX
22.54
  2.08  
+ 10.17%
1,055,859,000
22.56
8.87

Insider Trade Data

Date Insider Shares Type Value
12/15/2014 Bozigian, Haig P 12,498 Sell $279,255
12/15/2014 Bozigian, Haig P 12,498 Exchange $51,345
12/15/2014 Grigoriadis, Dimitri E 12,794 Sell $285,890
12/15/2014 Grigoriadis, Dimitri E 12,794 Exchange $52,111
12/12/2014 Gano, Kyle 4,043 Sell $90,968

Neurocrine Biosciences Inc. Executive(s):

Kevin Gorman

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
Subscribe Today!